Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 1.00 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709332 | 0.94 | LPAR1 (0.88) | LPAR1LPAR2LPAR5 | |
| SCHEMBL707554 | 0.93 | LPAR1 (0.86) | LPAR1LPAR2LPAR5 | |
| SCHEMBL708670 | 0.93 | LPAR1 (0.86) | LPAR1LPAR2 | |
| SCHEMBL708219 | 0.92 | LPAR1 (0.86) | LPAR1LPAR2 | |
| SCHEMBL709489 | 0.92 | LPAR1 (0.85) | LPAR1LPAR2LPAR5 | |
| SCHEMBL709497 | 0.92 | LPAR1 (0.85) | LPAR1LPAR2LPAR5 | |
| SCHEMBL708101 | 0.92 | LPAR1 (0.84) | LPAR1LPAR2 | |
| SCHEMBL708764 | 0.92 | LPAR1 (0.84) | LPAR1LPAR2LPAR5 | |
| SCHEMBL706763 | 0.92 | LPAR1 (0.84) | LPAR1LPAR2LPAR5 | |
| SCHEMBL708962 | 0.92 | LPAR1 (0.84) | LPAR1LPAR2LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | claimed |
| US-20240285587-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2024-08-29 | — | — | US | claimed |
| WO-2024157207-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2024-08-02 | — | — | WO | claimed |
| CN-118055777-A | Novel therapeutic agent for inhibiting metastasis and proliferation of osteosarcoma and glioma | 公益财团法人癌研究会 | 2024-05-17 | — | — | CN | claimed |
| EP-4360650-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | Japanese Foundation For Cancer Research (JP) | 2024-05-01 | — | — | EP | claimed |
| WO-2022270621-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | 公益財団法人がん研究会 | 2022-12-29 | — | — | WO | claimed |
| EP-4724096-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR Therapeutics, Inc. (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-20240285587-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2024-08-29 | — | — | US | disclosed |
| WO-2024157207-A1 | GPCR INHIBITORS AND USES THEREOF | GPCR THERAPEUTICS, INC. (KR) | 2024-08-02 | — | — | WO | disclosed |
| EP-4360650-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | Japanese Foundation For Cancer Research (JP) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022270621-A1 | NOVEL THERAPEUTIC AGENT THAT SUPPRESSES METASTASIS AND PROLIFERATION OF OSTEOSARCOMA AND GLIOMA | 公益財団法人がん研究会 | 2022-12-29 | — | — | WO | disclosed |
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO.,LTD. | 2008-03-13 | — | — | US | disclosed |
| US-7300917-B2 | Remedy for chronic disease | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-11-27 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| US-20060135577-A1 | Remedy for chronic disease | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR2 2/4885LPAR5 5/4885 |
| US-20080064731-A1 | REMEDY FOR CHRONIC DISEASE | EDNRA, EDNRB, LPAR2 | LPAR1 4/4885LPAR2 3/4885LPAR5 5/4885 |
| US-20060135577-A1 | Remedy for chronic disease | EDNRA, EDNRB, LPAR2 | LPAR1 4/4885LPAR2 3/4885LPAR5 5/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR2 2/4885LPAR5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.